Categories

·

In the AI-world, the value of ideas is dropping, including in drug discovery. A detailed discussion on the changes afoot to find where the real money sits in the new world

·

Massive reforms, global deals and proven FDA approvals suggest Chinese clinical data deserves far more credit than skeptical markets allow.

·

The untold story of how contract labs became a pharmaceutical superpower. China didn't just join the drug discovery race; it rewrote the rules.

·

China’s biopharma surge is policy-made: statutory clocks, silent approvals, and scaled expertise—creating a pipeline too fast to ignore

·

A look at the gap between popular AI narratives and the complex, world-changing reality of recent breakthroughs in materials, health, and logic.

·

Chinese pharma's breakthroughs are upending many important drivers and notions of the whole global healthcare industry

·

We evaluate five segments for the impact of AI, and feel that instrumentations may see the earliest winners

·

Of ignored innovations from segments where investor community is neither as detail-oriented nor as forward-thinking, optimistic